Regenovva

Executive Summary

Regenovva is a private biotechnology company based in San Diego, California, focused on developing novel regenerative medicine and cell therapies. Founded in 2015, the company's platform centers on Apolipoprotein E (ApoE) as an innate immune modulator, targeting life-threatening conditions such as sepsis and stroke. By restoring immune balance after infection or injury, Regenovva aims to address significant unmet needs in acute critical care. The company's approach leverages the natural immunomodulatory properties of ApoE to dampen harmful inflammation while preserving host defense, offering a potential therapeutic paradigm for disorders with high morbidity and mortality. Despite limited public information on funding or specific pipeline progress, Regenovva's focus on validated biology and serious indications positions it as an early-stage player with potential in the regenerative medicine space.

Upcoming Catalysts (preview)

• Q4 2026Initiation of First-in-Human Phase 1 Trial for Lead ApoE Program20% success
• Q3 2026Preclinical Proof-of-Concept Data Presentation at Major Conference40% success
• Q2 2026FDA Orphan Drug Designation for Sepsis or Stroke Indication30% success